Oncotarget

Corrections:

Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth

PDF  |  How to cite

Oncotarget. 2018; 9:36645-36645. https://doi.org/10.18632/oncotarget.26415

Metrics: PDF 464 views  |   ?  

Kimberley Hanson1, Stephen D. Robinson1, Karamallah Al-Yousuf2,3, Adam E. Hendry1, Darren W. Sexton4,5, Victoria Sherwood2,3 and Grant N. Wheeler1

1 School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK
2 School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK
3 Present address: Division of Cancer Sciences, School of Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK
4 Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK
5 Present address: Pharmacy and Biomedical Sciences, Liverpool John Moores University, Liverpool, L3 3AF, UK

Published: November 27, 2018

This article has been corrected: The correct Author name is given below:

Stephen D. Robinson

Original article: Oncotarget. 2018; 9:3815-3829. DOI: https://doi.org/10.18632/oncotarget.23378.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26415